Post-chemotherapy microscopic residual prostate rhabdomyosarcoma: long-term conservative follow-up.
In spite of advances in the treatment of childhood bladder and prostate rhabdomyosarcoma (RMS), the ability to detect minimal residual disease correlates imperfectly with the ultimate outcome. We report the long-term follow-up of a child with microscopic residual RMS after chemotherapy. The correct interpretation of the histologic findings spared the child unnecessary additional therapy and raises enigmatic questions about the biology of minimal residual disease.
Chertin
Boris
B
Department of Urology, Shaare Zedek Medical Center, Faculty of Health Science, Ben-Gurion University, Jerusalem, Israel.
Reinus
Constantin
C
Koulikov
Dmitry
D
Rosenmann
Eliezer
E
Farkas
Amicur
A
Chertin
B
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D018365:Neoplasm, Residual; D011471:Prostatic Neoplasms / Q000151:congenital / Q000188:drug therapy / Q000473:pathology*; D012208:Rhabdomyosarcoma / Q000151:congenital / Q000188:drug therapy / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000151:congenital / Q000188:drug therapy / Q000473:pathology*